바이오솔루션

086820KOSDAQ

40.0 / 100

Reference Date: 2026-10-23

Financial Score13.5 / 40

News Sentiment12.5 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Declined 13.0% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

BioSolution is a biotech company specializing in the research, development, and commercialization of advanced biopharmaceuticals, human tissue models, and biofusion materials based on stem cell and tissue engineering technologies. Key products include Kerahil for burn treatment and Catilife for cancer therapy, with OECD and ISO certifications enabling entry into alternative toxicity testing markets. The company also leads the clean and vegan cosmetics market through biofusion materials derived from plant stem cells and natural substances.

Number of Employees

100people

Average Salary

57.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

521.82Industry Average 15.000.0Point

34.8x industry avg (risky)

PBR

4.65Industry Average 1.200.0Point

3.9x industry avg (risky)

ROE

0.86Industry Average 8.001.0Point

Well below industry avg

Debt Ratio

7.08Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20254.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲10.7% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲6.8% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -11.5% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (3%, downtrend)

Current 5,740Won52-week high 12,95052-week low 5,510

1-month return1.0Point

1m -13.03% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0